Asset profile
CPL500036
Small molecule
Evidence outlook · lead readout
NCT05297201 · Parkinson Disease, Dyskinesia, Medication-Induced
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT05297201: The study was double-blind and placebo-controlled with 105 participants, and it used a clinical dyskinesia score as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Schizophrenia · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
120 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 120 same-indication; 87 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| CPL500036: this drug | Phase 2 | Small molecule | PDE10A | ||
| Amantadine ER (Gocovri / ADS-5102) | Approved | Small molecule | NMDA receptor | ||
| Apomorphine (Apokyn) | Approved | Small molecule | dopamine | ||
| Apomorphine Sublingual Film (Kynmobi) | Approved | Small molecule | dopamine | ||
| Aripiprazole (Abilify Maintena) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist) | ||
| Aripiprazole (Abilify MyCite) | Approved | Combination | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist) | ||
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole Lauroxil (Aristada Initio) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole Lauroxil (Aristada) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | ||
| Clozapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Crexont (IPX203) | Approved | Small molecule | dopamine precursor | ||
| Dexmedetomidine (Igalmi) | Approved | — | — | ||
| Dexmedetomidine (Igalmi) | Approved | Small molecule | Alpha-2 adrenergic receptor (agonist) |
…and 105 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.